Abrégé

The present invention relates to a sustained release pharmaceutical composition capable of forming in-situ implants and a preparation method therefor and, to a sustained release pharmaceutical composition capable of forming in-situ implants and a preparation method therefor, in which goserelin and a biodegradable polymer are each prepared into a sol state by being dissolved in a pharmaceutically acceptable solvent, and quickly transform into a solid state on a site after being administered thereto, so that initial drug release is suppressed and at the same time drug efficacy can be maintained for a long time period of more than one month with a single injection.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 38/09 - Hormone libérant l'hormone lutéinisante [LHRH]Peptides apparentés
• A61P 35/00 - Agents anticancéreux

Produits et services

Pharmaceutical preparations for treating sensory organ disorders; oral antiseptic; gargles for medical purposes; pharmaceutical preparations for treating gastrointestinal diseases; pharmaceutical preparations for treating cardiovascular diseases; pharmaceutical preparations for the central nervous system; pharmaceutical preparations for dental purposes; medicines for periodontal diseases; hormones for medical purposes; pharmaceutical preparations for respiratory diseases.

Abrégé

The present invention provides: a hyaluronic acid crosslinked product having both monophasic and biphasic characteristics; and, as a preparation method therefor, a method for preparing a granulated monophasic hyaluronic acid crosslinked product. The hyaluronic acid crosslinked product is characterized in that the ratio of viscosity and modulus of elasticity is 4:1 to 2:1. The hyaluronic acid cross-linked product of the present invention may be used as an injection in tissue.

Classes IPC  ?

• A61L 27/20 - Polysaccharides
• A61L 27/54 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
• A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol

Abrégé

The present invention relates to a composition for parenteral administration, containing donepezil as an active ingredient, and a preparation method therefor. Donepezil, which has been conventionally used for oral or transdermal administration, is prepared as microparticles comprising a biodegradable and biocompatible polymer and a release controller so as to be provided as a pharmaceutical composition for sustained release parenteral administration, thereby enabling in vivo sustained release continuously for 2-12 weeks or more. Therefore, it is possible to reduce the frequency of administration to a patient and maintain an effective concentration in the blood for a long time.

Classes IPC  ?

• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

The present invention relates to a composition for parenteral administration, containing donepezil as an active ingredient, and a preparation method therefor. Donepezil, which has been conventionally used for oral or transdermal administration, is prepared as microparticles comprising a biodegradable and biocompatible polymer and a release controller so as to be provided as a pharmaceutical composition for sustained release parenteral administration, thereby enabling in vivo sustained release continuously for 2-12 weeks or more. Therefore, it is possible to reduce the frequency of administration to a patient and maintain an effective concentration in the blood for a long time.

Classes IPC  ?

• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
• A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres

Abrégé

Provided is a process for preparing Voriconazole represented by Chemical Formula 1. More particularly, the process for preparing Voriconazole of Chemical Formula 1 includes: carrying out the Reformatsky-type coupling reaction between a ketone derivative of Chemical Formula 4 and a pyrimidine derivative of Chemical Formula 5 to obtain a compound of Chemical Formula 3; reacting the substituents halo and oxysulfonyl with a hydrogen donor to obtain racemic Voriconazole of Chemical Formula 2; and carrying out optical isolation of the racemic Voriconazole by adding an adequate optically active acid thereto to obtain Voriconazole having high optical purity with high cost-efficiency and high yield.

Classes IPC  ?

• C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques

Abrégé

Provided is a process for preparing Voriconazole represented by Chemical Formula 1. More particularly, the process for preparing Voriconazole of Chemical Formula 1 includes: carrying out the Reformatsky-type coupling reaction between a ketone derivative of Chemical Formula 4 and a pyrimidine derivative of Chemical Formula 5 to obtain a compound of Chemical Formula 3; reacting the substituents halo and oxysulfonyl with a hydrogen donor to obtain racemicVoriconazole of Chemical Formula 2; and carrying out optical isolation of the racemicVoriconazole by adding an adequate optically active acid thereto to obtain Voriconazole having high optical purity with high cost-efficiency and high yield.

Classes IPC  ?

• C07D 403/02 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles
• C07D 403/08 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles alicycliques

Abrégé

The present invention relates to a composition comprising the extract of Prunella vulgaris L for preventing and treating ADHD and the use thereof.

Classes IPC  ?

• A61K 36/536 - Prunella ou Brunella (brunelle)
• A23L 1/30 - contenant des additifs (A23L 1/308 a priorité);;
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

Disclosed is a method for preparing a longer sustained-release formulation containing bioactive substances. More particularly, the present invention provides a method for preparing longer sustained-release microcapsules comprising: adding an emulsion including bioactive substances, biocompatible polymer and polyvinylpyrrolidone to an aqueous solution.

Classes IPC  ?

• A61K 9/50 - Microcapsules

Abrégé

The present invention relates to a method for manufacturing a sustained release microsphere which is able to continuously control the release of a drug. More specifically, the present invention relates to a method for manufacturing a sustained release microsphere through a solvent flow evaporation method using a cosolvent when manufacturing a microsphere in which a drug is sealed in a carrier comprising biodegradable polymers. Thus, early excessive release of a physiologically active substance is suppressed so the physiologically active substance can be continuously and uniformly released in the body.

Classes IPC  ?

• A61K 9/16 - AgglomérésGranulésMicrobilles

Abrégé

Disclosed is a method for preparing a longer sustained-release formulation containing bioactive substances. More particularly, the present invention provides a method for preparing longer sustained-release microcapsules comprising : adding an emulsion including bioactive substances, biocompatible polymer and polyvinylpyrrolidone to an aqueous solution.

Classes IPC  ?

• B01J 13/02 - Fabrication de microcapsules ou de microbilles